Elvina Almuradova· @Dr_ElvinaA · X·· 2 天前评分70
正文 · 原文
Impressive ctDNA dynamics in B-STRONGER-I!
95.1% baseline detection in stage I–III TNBC.
By C3D1: 80.8% clearance and a 99.8% median reduction in ctDNA levels.
A striking window into early treatment response—before surgery.
#ESMO26 #TNBC #ctDNA @Larvol @OncoAlert
309 浏览 · 4 赞 · 6 转发 · 0 回复
会议摘要
LBA26按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Short-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trial
https://esmocongress.esmo.orgLBA96按 Proffered paper 2: Breast cancer, early and advanced stage 对上
First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Exploratory analysis of pts
https://esmocongress.esmo.org来源：Elvina Almuradova · x.com